Improving outcomes for people with MDS/MPN Overlap Syndromes
People with MDS/MPN Overlap Syndromes have very few treatment options available to them. This study will trial a new drug to see if it can extend and improve the lives of people with this disease.
MDS/MPN Overlap Syndromes are a rare type of blood cancer that has features of both MDS and MPN. There are limited treatments available for people with this disease. The disease can cause symptoms such as tiredness, infections, and bleeding and as there are limited treatments, the outlook isn’t good. We urgently need to find new treatments for this type of disease.
In this trial, the team will test a new drug called ASTX727 to see if it is able to improve outcomes for people with MDS/MPN Overlap Syndromes. The drug alters the pattern of how genes, some of which drive cancer growth, are turned on or off in a cancer cell and this drug will alter this to try and bring the cancer under control. The team want to understand if this drug improves symptoms and will compare the effects of this drug to patients receiving standard care. The drug is also given as a tablet which will reduce the need for patients to go to hospital, improving their overall quality of life.
If shown to be successful, the hope is that this drug may be able to improve and extend the lives of people with MDS/MPN Overlap Syndromes, giving them additional treatment options and an improved quality of life.